Combination therapy shows potent tumor growth inhibition in preclinical studies
Sunday, November 13, 2011 - 14:30
in Health & Medicine
Combining the investigational agents REGN910 and aflibercept yielded statistically significant improvements in antitumor effects in animal models compared with either agent alone, according to results presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011.